Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer.

Autor: Yang, James Chih-Hsin, Lee, Dae Ho, Lee, Jong-Seok, Fan, Yun, de Marinis, Filippo, Iwama, Eiji, Inoue, Takako, Rodríguez-Cid, Jerónimo, Zhang, Li, Yang, Cheng-Ta, de la Mora Jimenez, Emmanuel, Zhou, Jianying, Pérol, Maurice, Lee, Ki Hyeong, Vicente, David, Ichihara, Eiki, Riely, Gregory J., Luo, Yiwen, Chirovsky, Diana, Pietanza, M. Catherine

Publikováno v: Journal of Clinical Oncology; 12/1/2024, Vol. 42 Issue 34, p4029-4039, 20p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

Autor: Hellmann, Matthew, Paz-Ares, Luis, Bernabe Caro, Reyes, Zurawski, Bogdan, Kim, Sang-We, Carcereny Costa, Enric, Park, Keunchil, Alexandru, Aurelia, Lupinacci, Lorena, de La Mora Jimenez, Emmanuel, Sakai, Hiroshi, Albert, Istvan, Vergnenègre, Alain, Peters, Solange, Syrigos, Konstantinos, Barlesi, Fabrice, Reck, Martin, Borghaei, Hossein, Brahmer, Julie, O'Byrne, Kenneth, Geese, William, Bhagavatheeswaran, Prabhu, Rabindran, Sridhar, Kasinathan, Ravi, Nathan, Faith, Ramalingam, Suresh, O’byrne, Kenneth

Publikováno v: New England Journal of Medicine
r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
New England Journal of Medicine, 2019, 381 (21), pp.2020-2031. ⟨10.1056/NEJMoa1910231⟩
Digital.CSIC. Repositorio Institucional del CSIC
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
New England Journal of Medicine, Massachusetts Medical Society, 2019, 381 (21), pp.2020-2031. ⟨10.1056/NEJMoa1910231⟩

[Background] In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ad09d5c956f063b752bce70429dbbb
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1330

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Autor: Paz-Ares, Luis G., Ciuleanu, Tudor-Eliade, Cobo, Manuel, Bennouna, Jaafar, Schenker, Michael, Cheng, Ying, Juan-Vidal, Oscar, Mizutani, Hideaki, Lingua, Alejo, Reyes-Cosmelli, Felipe, Reinmuth, Niels, Menezes, Juliana, Jassem, Jacek, Protsenko, Svetlana, Richardet, Eduardo, Felip, Enriqueta, Feeney, Kynan, Zurawski, Bogdan, Alexandru, Aurelia, de la Mora Jimenez, Emmanuel, Dakhil, Shaker, Lu, Shun, Reck, Martin, John, Thomas, Hu, Nan, Zhang, Xiaoqing, Sylvester, Judi, Eccles, Laura J., Grootendorst, Diederik J., Balli, David, Neely, Jaclyn, Carbone, David P.

Publikováno v: Journal of Thoracic Oncology; 20220101, Issue: Preprints